NCT03046381View on ClinicalTrials.gov

Tocilizumab in Patients With Schnitzler's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

March 11, 2019

Study Completion Date

April 10, 2019

Conditions
Schnitzler's Syndrome
Interventions
DRUG

Tocilizumab

Tocilizumab 162mg 1x weekly s.c.

Trial Locations (1)

10117

Charité - Universitätsmedizin Berlin, Dpt. of Dermatology and Allergy, Berlin

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Karoline Krause

OTHER

NCT03046381 - Tocilizumab in Patients With Schnitzler's Syndrome | Biotech Hunter | Biotech Hunter